Hong Kong Exchanges and Clearing Limited (HKEX) will launch the Hang Seng Biotech Index Futures on 28 November 2025, expanding its derivatives product suite in one of Hong Kong’s fastest-growing market segments.
HKEX to Launch Hang Seng Biotech Index Futures in November
The new futures contract, which is subject to regulatory approval, will be based on the Hang Seng Biotech Index, which tracks the 30 largest southbound Stock Connect-eligible biotech, pharmaceutical, and medical device companies listed in Hong Kong.
Gregory Yu, HKEX’s Head of Markets, said: “Driven by innovation and strong global healthcare demand, the biotech industry is one of the most exciting frontiers in capital markets today.
He added that the new Hang Seng Biotech Index Futures will expand investor access to the sector’s potential and provide a “robust hedging tool.”
HKEX said the product would further support Hong Kong’s role as Asia’s leading derivatives and risk management hub, offering investors a way to manage exposure to one of the region’s most dynamic sectors.
Since HKEX’s 2018 listing reforms, biotech and healthcare listings have surged. More than 260 companies are now listed in the sector, with a combined market capitalisation exceeding HK$4.8 trillion, up 400% since 2018.
HKEX said margin rates and additional details will be announced ahead of the product’s launch.
